Literature DB >> 16107513

Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

J A P Da Silva1, J W G Jacobs, J R Kirwan, M Boers, K G Saag, L B S Inês, E J P de Koning, F Buttgereit, M Cutolo, H Capell, R Rau, J W J Bijlsma.   

Abstract

Adverse effects of glucocorticoids have been abundantly reported. Published reports on low dose glucocorticoid treatment show that few of the commonly held beliefs about their incidence, prevalence, and impact are supported by clear scientific evidence. Safety data from recent randomised controlled clinical trials of low dose glucocorticoid treatment in RA suggest that adverse effects associated with this drug are modest, and often not statistically different from those of placebo.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16107513      PMCID： PMC1798053          DOI： 10.1136/ard.2005.038638

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  150 in total

Review 1.  Nonassociation of adrenocorticosteroid therapy and peptic ulcer.

Authors:  H O Conn; B L Blitzer
Journal:  N Engl J Med       Date:  1976-02-26       Impact factor: 91.245

Review 2.  Corticosteroid osteoporosis.

Authors:  P Sambrook; N E Lane
Journal:  Best Pract Res Clin Rheumatol       Date:  2001-07       Impact factor: 4.098

3.  Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients.

Authors:  D M Becker; B Chamberlain; R Swank; M G Hegewald; R Girardet; K L Baughman; P O Kwiterovich; T A Pearson; W H Ettinger; D Renlund
Journal:  Am J Med       Date:  1988-11       Impact factor: 4.965

4.  Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms.

Authors:  D B Hellmann; M Petri; Q Whiting-O'Keefe
Journal:  Medicine (Baltimore)       Date:  1987-09       Impact factor: 1.889

5.  A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators.

Authors:  J W Mason; J B O'Connell; A Herskowitz; N R Rose; B M McManus; M E Billingham; T E Moon
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

6.  Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events.

Authors:  K G Saag; R Koehnke; J R Caldwell; R Brasington; L F Burmeister; B Zimmerman; J A Kohler; D E Furst
Journal:  Am J Med       Date:  1994-02       Impact factor: 4.965

7.  Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans.

Authors:  B M Frey; F J Frey
Journal:  Eur J Clin Invest       Date:  1984-02       Impact factor: 4.686

8.  Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature.

Authors:  D A Lewis; R E Smith
Journal:  J Affect Disord       Date:  1983-11       Impact factor: 4.839

9.  Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata.

Authors:  E A Olsen; S C Carson; E A Turney
Journal:  Arch Dermatol       Date:  1992-11

10.  Risk factors for coronary artery disease in patients with systemic lupus erythematosus.

Authors:  M Petri; S Perez-Gutthann; D Spence; M C Hochberg
Journal:  Am J Med       Date:  1992-11       Impact factor: 4.965
View more
  115 in total

Review 1.  Anti-inflammatory glucocorticoid drugs: reflections after 60 years.

Authors:  Michael W Whitehouse
Journal:  Inflammopharmacology       Date:  2010-10-31       Impact factor: 4.473

2.  The relationship between disease activity and depressive symptoms severity and optimism--results from the IMPROVED study.

Authors:  L Heimans; K V C Wevers-de Boer; K Visser; H K Ronday; G M Steup-Beekman; M van Oosterhout; T W J Huizinga; E J Giltay; R C van der Mast; C F Allaart
Journal:  Clin Rheumatol       Date:  2013-07-24       Impact factor: 2.980

3.  Preliminary prospective explanatory observation on the impact of 3-month steroid therapy on the objective measures of sleep-disordered breathing.

Authors:  Gidon Berger; Emilia Hardak; Beatrice Shaham; Emili Avitan; Mordechai Yigla
Journal:  Sleep Breath       Date:  2011-07-14       Impact factor: 2.816

Review 4.  Optimising corticosteroid treatment for autoimmune pancreatitis.

Authors:  Amaar Ghazale; Suresh T Chari
Journal:  Gut       Date:  2007-12       Impact factor: 23.059

5.  EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

Authors:  J N Hoes; J W G Jacobs; M Boers; D Boumpas; F Buttgereit; N Caeyers; E H Choy; M Cutolo; J A P Da Silva; G Esselens; L Guillevin; I Hafstrom; J R Kirwan; J Rovensky; A Russell; K G Saag; B Svensson; R Westhovens; H Zeidler; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2007-07-27       Impact factor: 19.103

6.  Inflammation, glucocorticoids and risk of cardiovascular disease.

Authors:  Frank Buttgereit; Gerd-Rüdiger Burmester; Brian J Lipworth
Journal:  Nat Clin Pract Rheumatol       Date:  2008-12-02

7.  [EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases].

Authors:  P Kolar; F Buttgereit
Journal:  Z Rheumatol       Date:  2009-06       Impact factor: 1.372

8.  Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Authors:  Zachary S Wallace; Eli M Miloslavsky; Matthew Cascino; Sebastian H Unizony; Na Lu; Gary S Hoffman; Cees G M Kallenberg; Carol A Langford; Peter A Merkel; Paul A Monach; Philip Seo; Robert Spiera; E William St Clair; Ulrich Specks; Paul Brunetta; Hyon K Choi; John H Stone
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-07       Impact factor: 4.794

9.  Muscle loss following a single high-dose intramuscular injection of corticosteroids to treat disease flare in patients with rheumatoid arthritis.

Authors:  Andrew B Lemmey; Thomas J Wilkinson; Celine M Perkins; Luke A Nixon; Fazal Sheikh; Jeremy G Jones; Yasmeen A Ahmad; Thomas D O'brien
Journal:  Eur J Rheumatol       Date:  2018-04-02

10.  Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists' practice for the monitoring of glucocorticoid eye toxicity.

Authors:  L Carli; C Tani; F Querci; A Della Rossa; S Vagnani; C Baldini; R Talarico; A d'Ascanio; R Neri; A G Tavoni; S Bombardieri; M Mosca
Journal:  Clin Rheumatol       Date:  2013-03-03       Impact factor: 2.980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.